| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Our comprehensive fluorescence in situ hybridization (FISH) panels simplify the ordering process to ensure every patient receives the right test. Our diagnostic panels were designed to align with testing requirements of the National Comprehensive Cancer Network (NCCN) and the CLL-International Prognostic Index (CLL-IPI).
FISH testing Test menu
The inclusion of the most relevant genetic probes into our adult, pediatric, and monitoring FISH panels enables detailed insights on diagnosis, prognosis, and treatment options, equipping providers and patients with confidence that nothing related to the disease state was missed. Our streamlined panels save time and expense incurred through sequential test ordering by providing precision insights at the beginning of a patient’s medical journey, ensuring they are on the best path forward.
Key testing
Additional testing
Highlights
VEXAS syndrome is a severe autoinflammatory disease that results in a spectrum of rheumatologic and hematologic conditions. The underlying cause of newly identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome — somatic mutations in the UBA1 gene of blood cells — was discovered at the National Institutes of Health (NIH) in 2020. Within six months, Mayo Clinic Laboratories was able to add a UBA1 test to the MayoComplete panel, as the team simultaneously worked on a single gene assay to allow doctors to test specifically for UBA1 mutations to screen patients for VEXAS syndrome. The team opted for a droplet digital PCR test — a novel and highly accurate approach to testing for UBA1 gene mutations.